Find syndicated market insights and custom brand analyses through our services offered in the gastroenterology market. Spherix’s independent research is conducted by our intelligence teams in collaboration with our proprietary network of gastroenterologists, patients, and leading KOLs.
More than one million Americans suffer from inflammatory bowel disease (IBD), divided between Crohn’s disease and ulcerative colitis. A distinguished physician-scientist and international leader in the treatment of IBD, Stephen B. Hanauer, MD , and his colleagues have come so far in understanding and treating IBD that their work may become a model for treating other immune-mediated inflammatory disorders, such as rheumatoid arthritis, psoriasis, and lupus. Hanauer joined Feinberg in January 2014 as the Clifford Joseph Barborka Professor of Medicine and the medical director of the Digestive Disease Center. He serves as chair of the International Organization for Inflammatory Bowel Disease, secretary-elect of the American College of Gastroenterology, and is a member of the GI Specialty Board of Internal Medicine, the American College of Physicians, and American Gastroenterology Association. He previously served as chair of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee, where he authored the FDA’s “Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease.”
Takeda’s Entyvio, Janssen’s Stelara, and AbbVie’s Humira leave the most on the table when first-line biologic or small molecule agents...
Despite satisfaction among gastroenterologists and allergists who have trialed the drug, high patient out-of-pocket costs and reimbursement hassles could hamper...
Rinvoq and Skyrizi are making waves in ulcerative colitis and Crohn’s disease; is Takeda’s Entyvio in the hot seat? EXTON,...
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and...
